A Phase 3 interventional study of abatacept (ABA) and placebo in Ulcerative Colitis, sponsored by Bristol-Myers Squibb. Completed at 144 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-24.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Colitis, Ulcerative by Bristol-Myers Squibb — 4 open to participants now, 5 under way, 1 of them phase 3. Colitis, Ulcerative · Bristol-Myers Squibb.
Among the 22 studies in Colitis, Ulcerative by Bristol-Myers Squibb, this one is the 3rd largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2006, is one of 5 in phase 3, and was the 2nd registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →4 of the 22 studies in Colitis, Ulcerative by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States
Women only
Bristol-Myers Squibb · Sites in Japan
Ages 18+
Bristol-Myers Squibb · Sites in Korea, Republic of
Ages 19+
Bristol-Myers Squibb · Sites in United States, Australia, Belgium and 10 more countries
Ages 2–17
By country, each count listing its studies:
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 6 · Phase 4 1
First in 2006; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 591 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 131 across the 17 interventional studies, 1,182 across the 5 observational. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
1 of the studies in Colitis, Ulcerative by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07271069Bristol-Myers SquibbEffectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Colitis, Ulcerative by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active ulcerative colitis in patients who have not had an adequate response to other therapies. The safety of this treatment will also be studied
The Induction Period First Cohort (IP1C) arms (30/10 mg/kg and 10 mg/kg) were placebo-controlled arms that were used for the primary endpoint and its analysis. The Induction Period Second Cohort arms (IP2C 30/10 mg/kg and 10 mg/kg) were not placebo-controlled, their sole purpose being to provide sufficient numbers of participants for the maintenance phase. The first cohort (IP1C) was randomized to receive placebo or 1 of 3 doses of abatacept. Following completion of the IP1C randomization, a second cohort (IP2C) was randomized to receive 1 of 2 doses of abatacept. After all participants in the IP1C completed or discontinued, the data was locked and the formal analysis for the Induction Period primary endpoint was performed. Summary tables for the second cohort (IP2C) and the Maintenance and Open-label phases were generated from a second, subsequent data lock.
Inclusion Criteria:
Induction Period; 3 arms for Cohort 1: ABA 30/\~10 mg/kg (ABA administered at 30 mg/kg followed by ABA at \~10 mg/kg), ABA \~10 mg/kg, ABA 3 mg/kg Induction Period; 2 arms for Cohort 2: ABA 30/\~10 mg/kg and Second Cohort ABA \~10 mg/kg 1 arm for maintenance period (ABA \~10 mg/kg)
Drug: abatacept (ABA)
1 arm for induction period 1 arm for maintenance period
Drug: placebo
1 arm for open-label extension phase (ABA \~10 mg/kg)
Drug: abatacept
Dextrose 5% in water, IV. Placebo on days IP-1, IP-15,IP-29, IP-57; 3 mg/kg on days IP-1, IP-15,IP-29, IP-57; 10 mg/kg on days IP-1, IP-15,IP-29, IP-57; or 30 mg/kg on days IP-1,IP-15 and \~10 mg/kg on days IP-29, IP-57 (ABA 30/\~10 mg/kg Group). Induction Period 3 months Maintenance Period 12 months
Also known as: Orencia, BMS-188667
Normal saline, IV, 0 mg/kg, every 28 days. Induction Period 3 months Maintenance Period 12 months
\~10 mg/kg, once monthly Open- Label Extension Period until the drug is marketed for UC or the UC development program for abatacept is discontinued
Also known as: Orencia, BMS-188667
Induction Period (IP); Number of Participants With Clinical Response (Per Mayo Score) at Week 12: IP Cohort 1 (IP1C)
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.
Time frame: Week 12 (Day IP-85)
Maintenance Period (MP); Number of Participants With Clinical Response (Per Mayo Score) at Month 12
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.
Time frame: Month 12 (Day MP-365)
Open-Label Extension Period (OL); Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
Time frame: Day OL-1 through the end of the OL
OL; Number of Participants With AEs of Special Interest
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).
Time frame: Day OL-1 through Day OL-729
OL; Number of Participants With Physical Examination Findings
Complete physical examination was obtained at the Screening Visit, Day MP-365, and OL Final Visit/Early Termination visits. Interim physical examinations were performed at other study visits. Interim physical exam were not as comprehensive as the initial full examination but did note any changes in the participant's condition since the last assessment and did not preclude examination of any of the body systems as clinically indicated. Participants were observed for AEs and vital signs (blood pressure, heart rate, and temperature).
Time frame: Day OL-1 through Day OL-729
OL; Number of Participants With Marked Hematology Laboratory Abnormalities
High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): \>3 g/dL decrease from Baseline (BL); Hematocrit: \<0.75 x BL; Erythrocytes: \<0.75 x BL; Platelets (PLT): \<0.67 x LLN/\>1.5 x ULN; Leukocytes: \<0.75 x LLN/ \>1.25 x ULN; neutrophils+bands: \<1.0 x 10\^3 c/uL; eosinophils: \>0.750 x 10\^3 c/uL; monocytes: \>2000 mm3; lymphocytes: \<0.750 x 10\^3 c/uL/ \>7.50 x 10\^3 c/uL.
Time frame: Day OL-1 through Day OL-729
OL; Number of Participants With Liver and Kidney Function and Electrolyte Laboratory Abnormalities
Low=lower than LLN, High=greater than ULN. LLN/ULN= Alkaline phosphatase (ALP): \>2 x ULN; aspartate aminotransferase (AST): \>3 x ULN; alanine aminotransferase (ALT): \>3 x ULN; G-Glutamyl transferase (GGT): \>2 x ULN; Bilirubin: \>2 x ULN; blood urea nitrogen (BUN): \>2 x BL; creatinine: \>4 x BL; potassium (K): \<0.9 x LLN/ \>1.1 x ULN; calcium (Ca): \<0.8 x LLN/\>1.2 x ULN; phosphorous (P): \<0.75 x LLN/ \>1.2 5 x ULN
Time frame: Day OL-1 through Day OL-729
OL; Number of Participants With Chemistry and Urinalysis Laboratory Abnormalities
Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): \<65 mg/dL/ \>220 mg/dL; fasting serum Glu: \<0.8 x LLN/ \>1.5 x ULN; total protein: \< 0.9 x LLN/ \>1.1 x ULN; albumin:\<0.9 x LLN; uric acid: \>1.5 x ULN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3
Time frame: Day OL-1 through Day OL-729
IP; Baseline Mayo Score: IP1C
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.
Time frame: Baseline
IP; Number of Participants in Clinical Remission (Per Mayo Score) at Week 12: IP1C
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.
Time frame: Week 12 (Day IP-85)
IP; Number of Participants in Mucosal Healing (Per Mayo Score) at Week 12: IP1C
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point
Time frame: Week 12 (Day IP-85)
IP; Number of Participants With Clinical Response (Per Mayo Score) at Week 12 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship: IP1C
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.
Time frame: Week 12 (Day IP-85)
IP; Baseline Inflammatory Bowel Disease Questionnaire (IBDQ) Score: IP1C
The Inflammatory Bowel Disease Questionnaire (IBDQ) was used to measure disease specific quality of life. The IBDQ consists of a self-administered 32-item questionnaire that evaluates quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. The response to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score can range between 32 to 224 with higher scores indicating a better quality of life.
Time frame: Baseline
IP; Mean Change From Baseline To Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ): IP1C
The Inflammatory Bowel Disease Questionnaire (IBDQ) was used to measure disease specific quality of life. The IBDQ consists of a self-administered 32-item questionnaire that evaluates quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. The response to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score can range between 32 to 224 with higher scores indicating a better quality of life.
Time frame: Baseline (Day IP-1), Day IP-85 (Week 12)
IP; Number of Participants With Mayo Rectal Bleeding Subscores Indicating Mild Disease (≤1 Point) at Week 12: IP1C
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute rectal bleeding subscore of ≤1 point was indicative of mild disease.
Time frame: Day IP-85 (Week 12)
IP; Number of Participants With Mayo Stool Frequency Subscores Indicating Mild Disease (≤1 Point) at Week 12: IP1C
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute stool frequency subscore of ≤1 point was indicative of mild disease.
Time frame: Day IP-85 (Week 12)
IP; Number of Participants With Mayo Physician Global Assessment (PGA) Subscores Indicating Mild Disease (≤1 Point) at Week 12: IP1C
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute PGA subscore of ≤1 point was indicative of mild disease.
Time frame: Day IP-85 (Week 12)
IP; Number of Participants Who Are Anti-TNF-Inadequate Responders/Anti-TNF Intolerant With Clinical Response At Week 12 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship: IP1C
The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Inadequate response/intolerance=inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.
Time frame: Week 12 (Day IP-85)
IP; Number of Participants With Clinical Response At Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C
The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Inadequate response/intolerance=inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.
Time frame: Week 12 (Day IP-85)
IP; Number of Participants in Clinical Remission at Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C
The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point. Inadequate response/intolerance =inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.
Time frame: Week 12 (Day IP-85)
IP; Number of Participants in Mucosal Healing at Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point. Inadequate response/intolerance = inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.
Time frame: Week 12 (Day IP-85)
IP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation: IP1C + IP2C
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
Time frame: Day IP-1 through Day IP-85
IP; Number of Participants With AEs Of Special Interest: IP1C + IP2C
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).
Time frame: Day IP-1 through Day IP-85
IP; Number of Participants With Physical Examination Findings: IP1C + IP2C
Complete physical examination was obtained at the Screening Visit, Day MP-365, and OL Final Visit/Early Termination visits. Interim physical examinations were performed at other study visits. Interim physical exam were not as comprehensive as the initial full examination but did note any changes in the participant's condition since the last assessment and did not preclude examination of any of the body systems as clinically indicated. Participants were observed for AEs and vital signs (blood pressure, heart rate, and temperature).
Time frame: Day IP-1 through Day IP-85
IP; Number of Participants With Marked Hematology Laboratory Abnormalities: IP1C
High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): \>3 g/dL decrease from Baseline (BL); Hematocrit: \<0.75 x BL; Erythrocytes: \<0.75 x BL; Platelets (PLT): \<0.67 x LLN/\>1.5 x ULN; Leukocytes: \<0.75 x LLN/ \>1.25 x ULN; neutrophils+bands: \<1.0 x 10\^3 c/uL; eosinophils: \>0.750 x 10\^3 c/uL; monocytes: \>2000 mm3; lymphocytes: \<0.750 x 10\^3 c/uL/ \>7.50 x 10\^3 c/uL.
Time frame: Day IP-1 through Day IP-85
IP; Number of Participants With Marked Liver and Kidney Function and Electrolyte Laboratory Abnormalities: IP1C
Low=lower than LLN, High=greater than ULN. LLN/ULN= Alkaline phosphatase (ALP): \>2 x ULN; aspartate aminotransferase (AST): \>3 x ULN; alanine aminotransferase (ALT): \>3 x ULN; G-Glutamyl transferase (GGT): \>2 x ULN; Bilirubin: \>2 x ULN; blood urea nitrogen (BUN): \>2 x BL; creatinine: \>4 x BL; Sodium (Na): \<0.95 x LLN/ \>1.05 x ULN; potassium (K): \<0.9 x LLN/ \>1.1 x ULN; calcium (Ca): \<0.8 x LLN/\>1.2 x ULN; phosphorous (P): \<0.75 x LLN/ \>1.2 5 x ULN
Time frame: Day IP-1 through Day IP-85
IP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities: IP1C
Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): \<65 mg/dL/ \>220 mg/dL; total protein: \< 0.9 x LLN/ \>1.1 x ULN; albumin:\<0.9 x LLN; uric acid: \>1.5 x ULN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3
Time frame: Day IP-1 through Day IP-85
IP; Number of Participants With Marked Hematology, Liver and Kidney Function, and Electrolyte Laboratory Abnormalities: IP2C
High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): \>3 g/dL decrease from Baseline (BL); Hematocrit: \<0.75 x BL; Erythrocytes: \<0.75 x BL; Platelets (PLT): \<0.67 x LLN/\>1.5 x ULN; Leukocytes: \<0.75 x LLN/ \>1.25 x ULN; eosinophils: \>0.750 x 10\^3 c/uL; monocytes: \>2000 mm3; lymphocytes: \<0.750 x 10\^3 c/uL/ \>7.50 x 10\^3 c/uL; blood urea nitrogen (BUN): \>2 x BL; creatinine: \>4 x BL; Sodium (Na): \<0.95 x LLN/ \>1.05 x ULN; potassium (K): \<0.9 x LLN/ \>1.1 x ULN; phosphorous (P): \<0.75 x LLN/ \>1.2 5 x ULN;
Time frame: Day IP-1 through Day IP-85
IP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities: IP2C
Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): \<65 mg/dL/ \>220 mg/dL; total protein: \< 0.9 x LLN/ \>1.1 x ULN; albumin:\<0.9 x LLN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3
Time frame: Day IP-1 through Day IP-85
IP; Number of Participants With Abatacept-Induced Antibodies: IP1C + IP2C
A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.
Time frame: For participants treated in MP: Day IP-1 (Baseline) to Day MP-1 (Day IP-85). For participants treated in OL directly after IP: Day IP-1 to Day OL-1. For participants treated only in IP: All measurements after Day IP-1 (including follow-up visits)
MP; Number of Participants in Clinical Remission at Month 12
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.
Time frame: Month 12 (Day MP-365)
MP; Number of Participants With Mayo Endoscopic Subscores Indicating Mucosal Healing (≤1 Point) at Month 12
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point
Time frame: Month 12 (Day MP-365)
MP; Number of Participants in Clinical Remission at Both Month 6 and Month 12
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.
Time frame: Month 6 (Day MP-169), Month 12 (Day MP-365)
MP; Number of Participants With Baseline Oral Corticosteroid Use Who Have Discontinued Corticosteroids and Achieved Clinical Remission by Month 12
Baseline corticosteroids equivalent of ≤30 mg prednisone daily. The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater frequency or severity. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.
Time frame: Day MP-365 (Month 12)
MP; Mean Change From Baseline to Month 12 in IBDQ
The Inflammatory Bowel Disease Questionnaire (IBDQ) was used to measure disease specific quality of life. The IBDQ consists of a self-administered 32-item questionnaire that evaluates quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. The response to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score can range between 32 to 224 with higher scores indicating a better quality of life.
Time frame: Day MP-365
MP; Mean Change From Baseline to Month 12 in Short Form-36 (SF-36)
The SF-36 is a validated instrument to measure health-related quality of life across multiple disease states. Individual subscale scores and 2 summary scores are calculated: (1) physical component summary (PCS) which includes physical functioning, role-physical, bodily pain, and general health; (2) mental component summary (MCS) which includes vitality, social functioning, role-emotional, and mental health. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight, with values ranging from worse health (0) to best health (100).
Time frame: Day MP-365
MP; Number of Participants With Baseline Oral Corticosteroid Use Who Have Discontinued Corticosteroids for 90 Consecutive Days and Achieved Clinical Remission by Month 12
Baseline corticosteroids equivalent of ≤30 mg prednisone daily. The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater frequency or severity. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.
Time frame: Day MP-365 (Month 12)
MP; Number of Participants With Mayo Rectal Bleeding Subscores Indicating Mild Disease (≤1 Point) at Month 12
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute rectal bleeding subscore of ≤1 point was indicative of mild disease.
Time frame: Day MP-365 (Month 12)
MP; Number of Participants With Mayo Stool Frequency Subscores Indicating Mild Disease (≤1 Point) at Month 12
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute stool frequency subscore of ≤1 point was indicative of mild disease.
Time frame: Day MP-365 (Month 12)
MP; Number of Participants With Mayo PGA Subscores Indicating Mild Disease (≤1 Point) at Month 12
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute PGA subscore of ≤1 point was indicative of mild disease.
Time frame: Day MP-365 (Month 12)
MP; Number of Participants With Clinical Response at Month 12 Among Participants With Inadequate Response/Intolerance to Prior Anti-TNF Therapy (Infliximab)
The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Inadequate response/intolerance=inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.
Time frame: Month 12 (Day MP-365)
MP; Number of Participants With Clinical Remission at Month 12 Among Participants With Inadequate Response/Intolerance to Prior Anti-TNF Therapy (Infliximab)
The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point. Inadequate response/intolerance =inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.
Time frame: Month 12 (Day MP-365)
MP; Number of Participants With Clinical Mucosal Healing at Month 12 Among Participants With Inadequate Response/Intolerance to Prior Anti-TNF Therapy (Infliximab)
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤1 point. Inadequate response/intolerance = inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.
Time frame: Month 12 (Day MP-365)
MP; Number of Participants With Abatacept-Induced Antibodies
A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.
Time frame: For participants not entering OL: All measurements starting after Day MP-1 (including follow-up visits). For participants entering OL: From first measurement after Day MP-1 to Day MP-365 (Day OL-1).
MP; Number of Participants With Adverse Events (AEs), Related AEs, Deaths, Serious AEs (SAEs), Related SAEs, and AEs Leading to Discontinuation
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
Time frame: Day MP-1 through Day MP-365
MP; Number of Participants With AEs of Special Interest
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).
Time frame: Day MP-1 through Day MP-365
MP; Number of Participants With Physical Examination Findings
Complete physical examination was obtained at the Screening Visit, Day MP-365, and OL Final Visit/Early Termination visits. Interim physical examinations were performed at other study visits. Interim physical exam were not as comprehensive as the initial full examination but did note any changes in the participant's condition since the last assessment and did not preclude examination of any of the body systems as clinically indicated. Participants were observed for AEs and vital signs (blood pressure, heart rate, and temperature).
Time frame: Day IP-85 through Day MP-365
MP; Number of Participants With Marked Hematology Laboratory Abnormalities
High=greater than ULN, Low=lower than LLN. LLN/ULN= HGB: \>3 g/dL decrease from Baseline (BL); Hematocrit: \<0.75 x BL; Erythrocytes: \<0.75 x BL; PLT: \<0.67 x LLN/\>1.5 x ULN; Leukocytes: \<0.75 x LLN/ \>1.25 x ULN; neutrophils+bands: \<1.0 x 10\^3 c/uL; eosinophils: \>0.750 x 10\^3 c/uL; monocytes: \>2000 mm3; lymphocytes: \<0.750 x 10\^3 c/uL/ \>7.50 x 10\^3 c/uL; GGT: \>2 x ULN; Bilirubin: \>2 x ULN; BUN: \>2 x BL; Na: \<0.95 x LLN/ \>1.05 x ULN; K: \<0.9 x LLN/ \>1.1 x ULN; Ca: \<0.8 x LLN/\>1.2 x ULN
Time frame: Day IP-85 through Day MP-365
MP; Number of Participants With Marked Chemistry and Urinalysis Laboratory Abnormalities
Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): \<65 mg/dL/ \>220 mg/dL; fasting serum Glu: \<0.8 x LLN/ \>1.5 x ULN; total protein: \< 0.9 x LLN/ \>1.1 x ULN; albumin:\<0.9 x LLN; uric acid: \>1.5 x ULN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3
Time frame: Day IP-85 through Day MP-365
OL; Number of Participants With Clinical Response Over Time
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.
Time frame: Day OL-1 through Day OL-729
OL; Number of Participants With Clinical Remission Over Time
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.
Time frame: Day OL-1 through Day OL-729
OL; Number of Participants With Mayo Endoscopic Subscores Indicating Mucosal Healing (≤1 Point) During OL
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point
Time frame: Open-Label Period (Day OL-1 through Day OL-729)
OL; Number of Participants With Clinical Response or Clinical Remission Upon Retreatment With Abatacept Among Those Who Received Abatacept in the IP or MP Period
The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Clinical remission = Mayo score of ≤ 2 points with no individual subscore exceeding 1 point. Change from Baseline= post-Baseline - Baseline value.
Time frame: Last Study Visit (Day OL-729)
OL; Number of Participants With Abatacept-Induced Antibodies
A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.
Time frame: For participants receiving OL medication, all measurements starting after Day OL-1 (including follow-up visits and at 56 and 85 days after last dose)
OL; Number of Participants Using Corticosteroids During OL
Participants taking oral corticosteroids (equivalent of ≤ 30 mg prednisone daily) must have met minimum treatment duration at entry into IP and had stable dose for ≥2 weeks prior to entry into the IP.
Time frame: Day OL-1 through Day OL-729
In this study, a first cohort (Induction Period First Cohort, IP1C) of 490 participants was randomized and used for analysis of the primary endpoint. Following randomization of IP1C, a second cohort (IP2C) of 146 participants was randomized to provide a sufficient number of participants for the Maintenance Period.
| Milestone | Induction Period Cohort 1 (IP1C)-Abatacept (ABA) 30/~10 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 3 mg/kg | IP1C-Placebo | IP Cohort 2 (IP2C)-ABA 30/~10 mg/kg | IP2C-ABA ~10 mg/kg | ABA ~10 mg/kg, Maintenance Period (MP) | Placebo, MP | ABA ~10 mg/kg, Open-Label Period (OL) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 141 | 139 | 70 | 140 | 51 | 50 | 0 | 0 | 0 |
| Completed | 106 | 104 | 53 | 120 | 19 | 21 | 0 | 0 | 0 |
| Not completed | 35 | 35 | 17 | 20 | 32 | 29 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 3 | 4 | 2 | 4 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 26 | 24 | 8 | 8 | 7 | 7 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 2 | 2 | 3 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 5 | 3 | 5 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Subject no longer meets study criteria | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Administrative reason by sponsor | 0 | 0 | 0 | 0 | 22 | 21 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Induction Period Cohort 1 (IP1C)-Abatacept (ABA) 30/~10 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 3 mg/kg | IP1C-Placebo | IP Cohort 2 (IP2C)-ABA 30/~10 mg/kg | IP2C-ABA ~10 mg/kg | ABA ~10 mg/kg, Maintenance Period (MP) | Placebo, MP | ABA ~10 mg/kg, Open-Label Period (OL) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 65 | 66 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 11 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 50 | 55 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 24 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Administrative reason by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 25 | 0 |
| Milestone | Induction Period Cohort 1 (IP1C)-Abatacept (ABA) 30/~10 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 3 mg/kg | IP1C-Placebo | IP Cohort 2 (IP2C)-ABA 30/~10 mg/kg | IP2C-ABA ~10 mg/kg | ABA ~10 mg/kg, Maintenance Period (MP) | Placebo, MP | ABA ~10 mg/kg, Open-Label Period (OL) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 349 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 349 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 161 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Administrative reason by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 145 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 |
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.
| participants | Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 3 mg/kg | IP1C-Placebo |
|---|---|---|---|---|
| Induction Period (IP); Number of Participants With Clinical Response (Per Mayo Score) at Week 12: IP Cohort 1 (IP1C) | 30 | 26 | 14 | 41 |
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.
| units on a scale | IP1C-ABA 30/~10 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 3 mg/kg, | IP1C-Placebo |
|---|---|---|---|---|
| IP; Baseline Mayo Score: IP1C | 8.9 ± 1.74 | 8.8 ± 1.73 | 8.6 ± 1.82 | 8.8 ± 1.59 |
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.
| participants | Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 3 mg/kg | IP1C-Placebo |
|---|---|---|---|---|
| IP; Number of Participants in Clinical Remission (Per Mayo Score) at Week 12: IP1C | 3 | 6 | 4 | 15 |
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point
| participants | Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 3 mg/kg | IP1C-Placebo |
|---|---|---|---|---|
| IP; Number of Participants in Mucosal Healing (Per Mayo Score) at Week 12: IP1C | 24 | 20 | 11 | 36 |
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.
| participants | IP1C-Placebo | IP1C-ABA 3 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 30/~10 mg/kg |
|---|---|---|---|---|
| IP; Number of Participants With Clinical Response (Per Mayo Score) at Week 12 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship: IP1C | 41 | 14 | 26 | 30 |
The Inflammatory Bowel Disease Questionnaire (IBDQ) was used to measure disease specific quality of life. The IBDQ consists of a self-administered 32-item questionnaire that evaluates quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. The response to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score can range between 32 to 224 with higher scores indicating a better quality of life.
| units on a scale | IP1C-ABA 30/~10 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 3 mg/kg, | IP1C-Placebo |
|---|---|---|---|---|
| IP; Baseline Inflammatory Bowel Disease Questionnaire (IBDQ) Score: IP1C | 120.0 ± 35.43 | 121.5 ± 36.42 | 126.9 ± 35.93 | 124.3 ± 33.43 |
The Inflammatory Bowel Disease Questionnaire (IBDQ) was used to measure disease specific quality of life. The IBDQ consists of a self-administered 32-item questionnaire that evaluates quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. The response to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score can range between 32 to 224 with higher scores indicating a better quality of life.
| units on a scale | Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 3 mg/kg | IP1C-Placebo |
|---|---|---|---|---|
| IP; Mean Change From Baseline To Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ): IP1C | 9.45 ± 3.514 | 13.36 ± 3.476 | 9.87 ± 5.108 | 23.68 ± 3.268 |
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute rectal bleeding subscore of ≤1 point was indicative of mild disease.
| participants | Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 3 mg/kg | IP1C-Placebo |
|---|---|---|---|---|
| Rectal Subscore=0 | 28 | 36 | 16 | 47 |
| Rectal Subscore=1 | 31 | 30 | 13 | 27 |
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute stool frequency subscore of ≤1 point was indicative of mild disease.
| participants | Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 3 mg/kg | IP1C-Placebo |
|---|---|---|---|---|
| Stool Frequency Subscore=0 | 13 | 8 | 4 | 14 |
| Stool Frequency Subscore=1 | 14 | 21 | 10 | 32 |
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute PGA subscore of ≤1 point was indicative of mild disease.
| participants | Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 3 mg/kg | IP1C-Placebo |
|---|---|---|---|---|
| PGA Subscore=0 | 2 | 4 | 3 | 11 |
| PGA Subscore=1 | 22 | 25 | 15 | 34 |
The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Inadequate response/intolerance=inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.
| participants | IP1C-Placebo | IP1C-ABA 3 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 30/~10 mg/kg |
|---|---|---|---|---|
| IP; Number of Participants Who Are Anti-TNF-Inadequate Responders/Anti-TNF Intolerant With Clinical Response At Week 12 Analyzed by Cochran-Armitage Trend Test for Dose-Response Relationship: IP1C | 12 | 4 | 7 | 8 |
The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Inadequate response/intolerance=inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.
| participants | Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 3 mg/kg | IP1C-Placebo |
|---|---|---|---|---|
| IP; Number of Participants With Clinical Response At Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C | 8 | 7 | 4 | 12 |
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.
| participants | ABA ~10 mg/kg, MP | Placebo, MP |
|---|---|---|
| Maintenance Period (MP); Number of Participants With Clinical Response (Per Mayo Score) at Month 12 | 11 | 11 |
The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point. Inadequate response/intolerance =inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.
| participants | Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 3 mg/kg | IP1C-Placebo |
|---|---|---|---|---|
| IP; Number of Participants in Clinical Remission at Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C | 2 | 0 | 0 | 4 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
| participants | ABA ~10 mg/kg, OL |
|---|---|
| AEs | 241 |
| Related AEs | 100 |
| Deaths | 1 |
| SAEs | 66 |
| Related SAEs | 9 |
| AEs Leading to Discontinuation | 7 |
| SAEs Leading to Discontinuation | 4 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).
| participants | ABA ~10 mg/kg, OL |
|---|---|
| Infections and Infestations | 127 |
| Serious Infections | 9 |
| Opportunistic Infections-Total | 2 |
| Opportunistic Infections-cytomegalovirus | 1 |
| Opportunistic Infections-listeriosis | 1 |
| Malignancies-Total | 5 |
| Malignancies-Basal Cell Carcinoma | 2 |
| Malignancies-Bowen's Disease | 1 |
| Malignancies-Chronic Myeloid Leukemia | 1 |
| Malignancies-Squamous Cell Carcinoma | 1 |
| Autoimmune Disorders-Total | 5 |
| Autoimmune Disorders-episcleritis | 2 |
| Autoimmune Disorders-scleritis | 1 |
| Autoimmune Disorders-anemia hemolytic autoimmune | 1 |
| Autoimmune Disorders-psoriasis | 1 |
| Acute Infusional AEs | 12 |
| Peri-infusional AEs | 25 |
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point. Inadequate response/intolerance = inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.
| participants | Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 3 mg/kg | IP1C-Placebo |
|---|---|---|---|---|
| IP; Number of Participants in Mucosal Healing at Week 12 Among Participants With Anti-TNF (Infliximab) Failure/Intolerance: IP1C | 4 | 4 | 1 | 13 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
| participants | IP1C-ABA 30/~10 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 3 mg/kg, | IP1C-Placebo | IP Cohort 2 (IP2C)-ABA 30/~10 mg/kg | IP2C-ABA ~10 mg/kg |
|---|---|---|---|---|---|---|
| AEs | 85 | 92 | 39 | 86 | 26 | 27 |
| Related AEs | 48 | 46 | 23 | 37 | 10 | 11 |
| Deaths | 1 | 0 | 0 | 0 | 0 | 0 |
| SAEs | 22 | 20 | 8 | 7 | 6 | 4 |
| Related SAEs | 4 | 1 | 1 | 3 | 1 | 0 |
| AEs Leading to Discontinuation | 4 | 6 | 2 | 5 | 1 | 0 |
| SAEs Leading to Discontinuation | 1 | 2 | 1 | 3 | 1 | 0 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).
| participants | IP1C-ABA 30/~10 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 3 mg/kg, | IP1C-Placebo | IP Cohort 2 (IP2C)-ABA 30/~10 mg/kg | IP2C-ABA ~10 mg/kg |
|---|---|---|---|---|---|---|
| Infections and Infestations | 23 | 29 | 8 | 25 | 12 | 7 |
| Serious Infections | 5 | 0 | 1 | 0 | 0 | 0 |
| Opportunistic Infections-Total | 0 | 1 | 1 | 0 | 0 | 0 |
| Opportunistic Infections-candidiasis | 0 | 0 | 1 | 0 | 0 | 0 |
| Opportunistic Infections-esophageal candidiasis | 0 | 1 | 0 | 0 | 0 | 0 |
| Malignancies-Total | 1 | 0 | 0 | 1 | 0 | 0 |
| Malignancies-basal cell carcinoma | 1 | 0 | 0 | 0 | 0 | 0 |
| Malignancies-malignant melanoma | 0 | 0 | 0 | 1 | 0 | 0 |
| Autoimmune Disorders-Total | 2 | 1 | 0 | 4 | 0 | 0 |
| Autoimmune Disorders-uveitis | 1 | 1 | 0 | 1 | 0 | 0 |
| Autoimmune Disorders-episcleritis | 0 | 0 | 0 | 1 | 0 | 0 |
| Autoimmune Disorders-scleritis | 0 | 0 | 0 | 1 | 0 | 0 |
| Autoimmune Disorders-rheumatoid arthritis | 0 | 0 | 0 | 1 | 0 | 0 |
| Autoimmune Disorders-psoriasis | 1 | 0 | 0 | 0 | 0 | 0 |
| Acute Infusional AEs | 4 | 4 | 0 | 2 | 0 | 0 |
| Peri Infusional AEs | 17 | 20 | 5 | 14 | 2 | 4 |
Complete physical examination was obtained at the Screening Visit, Day MP-365, and OL Final Visit/Early Termination visits. Interim physical examinations were performed at other study visits. Interim physical exam were not as comprehensive as the initial full examination but did note any changes in the participant's condition since the last assessment and did not preclude examination of any of the body systems as clinically indicated. Participants were observed for AEs and vital signs (blood pressure, heart rate, and temperature).
No measurements were reported for this outcome.
High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): \>3 g/dL decrease from Baseline (BL); Hematocrit: \<0.75 x BL; Erythrocytes: \<0.75 x BL; Platelets (PLT): \<0.67 x LLN/\>1.5 x ULN; Leukocytes: \<0.75 x LLN/ \>1.25 x ULN; neutrophils+bands: \<1.0 x 10\^3 c/uL; eosinophils: \>0.750 x 10\^3 c/uL; monocytes: \>2000 mm3; lymphocytes: \<0.750 x 10\^3 c/uL/ \>7.50 x 10\^3 c/uL.
| participants | IP1C-ABA 30/~10 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 3 mg/kg, | IP1C-Placebo |
|---|---|---|---|---|
| Low HGB; n=136, n=134, n=67, n=133 | 3 | 2 | 6 | 1 |
| Low hematocrit; n=134, n=133, n=67, n=131 | 1 | 2 | 4 | 1 |
| Low erythrocytes; n=136, n=134, n=67, n=133 | 2 | 2 | 4 | 1 |
| Low PLT; n=136, n=133, n=66, n=133 | 1 | 0 | 1 | 0 |
| High PLT; n=136, n=133, n=66, n=133 | 0 | 2 | 0 | 0 |
| Low leukocytes; n=136, n=134, n=67, n=133 | 1 | 0 | 4 | 1 |
| High leukocytes; n=136, n=134, n=67, n=133 | 10 | 6 | 3 | 5 |
| Low neutrophils + bands; n=136, n=134, n=67, n=131 | 0 | 0 | 1 | 0 |
| High eosinophils; n=136, n=134, n=67, n=131 | 6 | 4 | 3 | 4 |
| High monocytes; n=136, n=134, n=67, n=131 | 0 | 0 | 1 | 0 |
| Low lymphocytes; n=136, n=134, n=67, n=131 | 23 | 13 | 11 | 26 |
Low=lower than LLN, High=greater than ULN. LLN/ULN= Alkaline phosphatase (ALP): \>2 x ULN; aspartate aminotransferase (AST): \>3 x ULN; alanine aminotransferase (ALT): \>3 x ULN; G-Glutamyl transferase (GGT): \>2 x ULN; Bilirubin: \>2 x ULN; blood urea nitrogen (BUN): \>2 x BL; creatinine: \>4 x BL; Sodium (Na): \<0.95 x LLN/ \>1.05 x ULN; potassium (K): \<0.9 x LLN/ \>1.1 x ULN; calcium (Ca): \<0.8 x LLN/\>1.2 x ULN; phosphorous (P): \<0.75 x LLN/ \>1.2 5 x ULN
| participants | IP1C-ABA 30/~10 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 3 mg/kg, | IP1C-Placebo |
|---|---|---|---|---|
| High ALP, n=137, n=135, n=66, n=135 | 1 | 0 | 0 | 0 |
| High ALT; n=137, n=135, n=66, n=135 | 0 | 1 | 0 | 0 |
| High GGT; n=137, n=135, n=66, n=135 | 6 | 2 | 0 | 2 |
| High BUN; n=127, n=130, n=62, n=124 | 0 | 2 | 2 | 3 |
| High creatinine; n=137, n=135, n=66, n=135 | 0 | 0 | 0 | 1 |
| Low Na; n=138, n=135, n=66, n=135 | 0 | 0 | 2 | 0 |
| Low K; n=138, n=135, n=66, n=135 | 1 | 2 | 2 | 0 |
| High K; n=138, n=135, n=66, n=135 | 0 | 1 | 0 | 1 |
| Low Ca; n=137, n=135, n=66, n=135 | 0 | 1 | 2 | 0 |
| Low P; n=137, 135, n=66, n=135 | 0 | 1 | 0 | 3 |
Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): \<65 mg/dL/ \>220 mg/dL; total protein: \< 0.9 x LLN/ \>1.1 x ULN; albumin:\<0.9 x LLN; uric acid: \>1.5 x ULN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3
| participants | IP1C-ABA 30/~10 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 3 mg/kg, | IP1C-Placebo |
|---|---|---|---|---|
| Low Glu; n=88, n=91, n=41, n=105 | 1 | 6 | 2 | 0 |
| High Glu; n=88, n=91, n=41, n=105 | 0 | 0 | 1 | 0 |
| Low protein; n=137, n=135, n=66, n=135 | 5 | 3 | 3 | 0 |
| High protein; n=137, n=135, n=66, n=135 | 0 | 1 | 0 | 0 |
| Low albumin; n=137, n=135, n=66, n=135 | 7 | 5 | 3 | 0 |
| High urine protein; n=132, n=129, n=66, n=128 | 5 | 3 | 2 | 4 |
| High urine Glu; n=132, n=129, n=66, n=128 | 4 | 1 | 2 | 4 |
| High urine blood; n=132, n=129, n=66, n=128 | 6 | 7 | 4 | 11 |
| High leukocyte esterase; n=54, n=51, n=27, n=52 | 1 | 5 | 2 | 2 |
| High urine RBC; n=47, n=42, n=17, n=52 | 9 | 8 | 4 | 12 |
| High urine WBC; n=64, n=56, n=27, n=58 | 14 | 21 | 3 | 14 |
High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): \>3 g/dL decrease from Baseline (BL); Hematocrit: \<0.75 x BL; Erythrocytes: \<0.75 x BL; Platelets (PLT): \<0.67 x LLN/\>1.5 x ULN; Leukocytes: \<0.75 x LLN/ \>1.25 x ULN; eosinophils: \>0.750 x 10\^3 c/uL; monocytes: \>2000 mm3; lymphocytes: \<0.750 x 10\^3 c/uL/ \>7.50 x 10\^3 c/uL; blood urea nitrogen (BUN): \>2 x BL; creatinine: \>4 x BL; Sodium (Na): \<0.95 x LLN/ \>1.05 x ULN; potassium (K): \<0.9 x LLN/ \>1.1 x ULN; phosphorous (P): \<0.75 x LLN/ \>1.2 5 x ULN;
| participants | IP2C-ABA 30/~10 mg/kg | IP2C-ABA ~10 mg/kg |
|---|---|---|
| Low HGB; n=50, n=49 | 2 | 2 |
| Low hematocrit; n=50, n=49 | 1 | 0 |
| Low erythrocytes; n=50, n=49 | 1 | 0 |
| High PLT; n=50, n=49 | 0 | 1 |
| Low leukocytes; n=50, n=49 | 0 | 1 |
| High leukocytes; n=50, n=49 | 3 | 4 |
| High eosinophils; n=49, n=49 | 3 | 1 |
| High monocytes; n=49, n=49 | 0 | 1 |
| Low lymphocytes; n=49, n=49 | 5 | 3 |
| High BUN; n=46, n=44 | 3 | 1 |
| High creatinine; n=50, n=50 | 1 | 0 |
| Low Na; n=50, n=50 | 1 | 0 |
| Low K; n=50, n=50 | 2 | 1 |
| Low P; n=50, n=50 | 1 | 0 |
| Low Glu; n=37, n=28 | 0 | 2 |
| High Glu; n=37, n=28 | 0 | 2 |
| Low protein; n=50, n=50 | 2 | 0 |
| Low albumin; n=50, n=50 | 2 | 0 |
| High urine protein; n=50, n=48 | 0 | 4 |
| High urine Glu; n=50, n=48 | 0 | 2 |
| High urine blood; n=50, n=48 | 2 | 3 |
| High leukocyte esterase; n=21, n=16 | 4 | 2 |
| High urine RBC; n=15, n=20 | 0 | 4 |
| High urine WBC; n=24, n=23 | 7 | 6 |
Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): \<65 mg/dL/ \>220 mg/dL; total protein: \< 0.9 x LLN/ \>1.1 x ULN; albumin:\<0.9 x LLN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3
| participants | IP2C-ABA 30/~10 mg/kg | IP2C-ABA ~10 mg/kg |
|---|---|---|
| Low Glu; n=37, n=28 | 0 | 2 |
| High Glu; n=37, n=28 | 0 | 2 |
| Low protein; n=50, n=50 | 2 | 0 |
| Low albumin; n=50, n=50 | 2 | 0 |
| High urine protein; n=50, n=48 | 0 | 4 |
| High urine Glu; n=50, n=48 | 0 | 2 |
| High urine blood; n=50, n=48 | 2 | 3 |
| High leukocyte esterase; n=21, n=16 | 4 | 2 |
| High urine RBC; n=15, n=20 | 0 | 4 |
| High urine WBC; n=24, n=23 | 7 | 6 |
A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.
| participants | IP1C+IP2C: ABA 30/~10 mg/kg | IP1C+IP2C: ABA ~10 mg/kg | IP1C-ABA 3 mg/kg |
|---|---|---|---|
| Total | 6 | 19 | 4 |
| CTLA4/Possibly Ig | 2 | 17 | 4 |
| Ig and/or Ig Junction | 4 | 3 | 0 |
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.
| participants | ABA ~10 mg/kg, MP | Placebo, MP |
|---|---|---|
| MP; Number of Participants in Clinical Remission at Month 12 | 8 | 9 |
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point
| participants | ABA ~10 mg/kg, MP | Placebo, MP |
|---|---|---|
| MP; Number of Participants With Mayo Endoscopic Subscores Indicating Mucosal Healing (≤1 Point) at Month 12 | 11 | 10 |
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.
No measurements were reported for this outcome.
Baseline corticosteroids equivalent of ≤30 mg prednisone daily. The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater frequency or severity. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.
No measurements were reported for this outcome.
The Inflammatory Bowel Disease Questionnaire (IBDQ) was used to measure disease specific quality of life. The IBDQ consists of a self-administered 32-item questionnaire that evaluates quality of life across 4 dimensional scores: Bowel, Systemic, Social and Emotional. The response to each question can range from 1 to 7, with 1 indicating severe problem and 7 indicating normal health. The total IBDQ is computed as the sum of the responses to the individual IBDQ questions. The total score can range between 32 to 224 with higher scores indicating a better quality of life.
No measurements were reported for this outcome.
The SF-36 is a validated instrument to measure health-related quality of life across multiple disease states. Individual subscale scores and 2 summary scores are calculated: (1) physical component summary (PCS) which includes physical functioning, role-physical, bodily pain, and general health; (2) mental component summary (MCS) which includes vitality, social functioning, role-emotional, and mental health. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight, with values ranging from worse health (0) to best health (100).
No measurements were reported for this outcome.
Baseline corticosteroids equivalent of ≤30 mg prednisone daily. The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater frequency or severity. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.
No measurements were reported for this outcome.
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute rectal bleeding subscore of ≤1 point was indicative of mild disease.
No measurements were reported for this outcome.
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute stool frequency subscore of ≤1 point was indicative of mild disease.
No measurements were reported for this outcome.
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. An absolute PGA subscore of ≤1 point was indicative of mild disease.
No measurements were reported for this outcome.
The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Inadequate response/intolerance=inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.
No measurements were reported for this outcome.
The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point. Inadequate response/intolerance =inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.
No measurements were reported for this outcome.
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤1 point. Inadequate response/intolerance = inadequate response/intolerance to an approved anti-TNF agent prior to this study at an approved labeled dose for ≥8 weeks.
No measurements were reported for this outcome.
A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.
| participants | ABA ~10 mg/kg, MP | Placebo, MP |
|---|---|---|
| Total | 8 | 20 |
| CTLA4/Possibly Ig | 8 | 17 |
| Ig and/or Ig Junction | 0 | 3 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
| participants | ABA ~10 mg/kg, MP | Placebo, MP |
|---|---|---|
| AEs | 39 | 36 |
| Related AEs | 12 | 13 |
| Deaths | 1 | 0 |
| SAEs | 7 | 4 |
| Related SAEs | 2 | 2 |
| AEs Leading to Discontinuation | 1 | 3 |
| SAEs Leading to Discontinuation | 1 | 1 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, and opportunistic infections; autoimmune disorders; neoplasms; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion).
| participants | ABA ~10 mg/kg, MP | Placebo, MP |
|---|---|---|
| Infections and Infestations | 39 | 36 |
| Serious Infections | 5 | 2 |
| Opportunistic Infections-Total | 1 | 0 |
| Opportunistic Infections-pneumonia herpes viral | 1 | 0 |
| Malignancies-Total | 0 | 1 |
| Malignancies-breast cancer | 0 | 1 |
| Autoimmune Disorders-Total | 2 | 0 |
| Autoimmune Disorders-erythema nodosum | 1 | 0 |
| Autoimmune Disorders-pemphigoid | 1 | 0 |
| Acute Infusional AEs | 2 | 1 |
| Peri-infusional AEs | 3 | 2 |
Complete physical examination was obtained at the Screening Visit, Day MP-365, and OL Final Visit/Early Termination visits. Interim physical examinations were performed at other study visits. Interim physical exam were not as comprehensive as the initial full examination but did note any changes in the participant's condition since the last assessment and did not preclude examination of any of the body systems as clinically indicated. Participants were observed for AEs and vital signs (blood pressure, heart rate, and temperature).
No measurements were reported for this outcome.
High=greater than ULN, Low=lower than LLN. LLN/ULN= HGB: \>3 g/dL decrease from Baseline (BL); Hematocrit: \<0.75 x BL; Erythrocytes: \<0.75 x BL; PLT: \<0.67 x LLN/\>1.5 x ULN; Leukocytes: \<0.75 x LLN/ \>1.25 x ULN; neutrophils+bands: \<1.0 x 10\^3 c/uL; eosinophils: \>0.750 x 10\^3 c/uL; monocytes: \>2000 mm3; lymphocytes: \<0.750 x 10\^3 c/uL/ \>7.50 x 10\^3 c/uL; GGT: \>2 x ULN; Bilirubin: \>2 x ULN; BUN: \>2 x BL; Na: \<0.95 x LLN/ \>1.05 x ULN; K: \<0.9 x LLN/ \>1.1 x ULN; Ca: \<0.8 x LLN/\>1.2 x ULN
| participants | ABA 30/~10 mg/kg, MP | ABA ~10 mg/kg, MP |
|---|---|---|
| Low HGB; n=64, n=61 | 1 | 2 |
| Low hematocrit; n=64, n=60 | 3 | 2 |
| Low erythrocytes; n=64, n=61 | 1 | 2 |
| High PLT; n= 64, n=61 | 0 | 1 |
| Low leukocytes; n=64, n=60 | 2 | 0 |
| High leukocytes; n=64, n=60 | 2 | 0 |
| Low neutrophils + bands; n=64, n=60 | 1 | 0 |
| High eosinophils; n=64, n=60 | 2 | 3 |
| High monocytes; n=64, n=60 | 1 | 0 |
| Low lymphocytes; n=64, n=60 | 7 | 6 |
| High lymphocytes; n=64, n=60 | 1 | 0 |
| High GGT; n=64, n=62 | 3 | 2 |
| High bilirubin, n=64, n=61 | 1 | 0 |
| High BUN; n=57, n=59 | 4 | 3 |
| Low Na; n=64, n=62 | 0 | 1 |
| Low K; n=64, n=62 | 1 | 1 |
| Low Ca; n=64, n=61 | 1 | 0 |
| Low Glu; n=45, n=38 | 0 | 2 |
| High Glu; n=45, n=38 | 3 | 3 |
| Low protein; n=64, n=61 | 0 | 1 |
| High urine protein; n=58, n=58 | 4 | 1 |
| High urine Glu; n=58, n=58 | 2 | 1 |
| High urine blood; n=58, n=58 | 3 | 7 |
| High leukocyte esterase; n=23, n=18 | 2 | 5 |
| High urine RBC; n=24, n=17 | 4 | 4 |
| High urine WBC; n=29, n=21 | 8 | 10 |
Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): \<65 mg/dL/ \>220 mg/dL; fasting serum Glu: \<0.8 x LLN/ \>1.5 x ULN; total protein: \< 0.9 x LLN/ \>1.1 x ULN; albumin:\<0.9 x LLN; uric acid: \>1.5 x ULN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3
| participants | ABA 30/~10 mg/kg, MP | ABA ~10 mg/kg, MP |
|---|---|---|
| Low Glu; n=45, n=38 | 0 | 2 |
| High Glu; n=45, n=38 | 3 | 3 |
| Low protein; n=64, n=61 | 0 | 1 |
| High urine protein; n=58, n=58 | 4 | 1 |
| High urine Glu; n=58, n=58 | 2 | 1 |
| High urine blood; n=58, n=58 | 3 | 7 |
| High leukocyte esterase; n=23, n=18 | 2 | 5 |
| High urine RBC; n=24, n=17 | 4 | 4 |
| High urine WBC; n=29, n=21 | 8 | 10 |
Complete physical examination was obtained at the Screening Visit, Day MP-365, and OL Final Visit/Early Termination visits. Interim physical examinations were performed at other study visits. Interim physical exam were not as comprehensive as the initial full examination but did note any changes in the participant's condition since the last assessment and did not preclude examination of any of the body systems as clinically indicated. Participants were observed for AEs and vital signs (blood pressure, heart rate, and temperature).
No measurements were reported for this outcome.
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.
| participants | ABA ~10 mg/kg, OL |
|---|---|
| Day OL-365 (n=163) | 44 |
| Day OL-729 (n=4) | 0 |
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Clinical remission is defined as a Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.
| participants | ABA ~10 mg/kg, OL |
|---|---|
| Day OL-365 (n=163) | 18 |
| Day OL-729 (n=4) | 0 |
High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): \>3 g/dL decrease from Baseline (BL); Hematocrit: \<0.75 x BL; Erythrocytes: \<0.75 x BL; Platelets (PLT): \<0.67 x LLN/\>1.5 x ULN; Leukocytes: \<0.75 x LLN/ \>1.25 x ULN; neutrophils+bands: \<1.0 x 10\^3 c/uL; eosinophils: \>0.750 x 10\^3 c/uL; monocytes: \>2000 mm3; lymphocytes: \<0.750 x 10\^3 c/uL/ \>7.50 x 10\^3 c/uL.
| participants | ABA ~10 mg/kg, OL |
|---|---|
| Low HGB; n=326 | 20 |
| Low hematocrit; n=322 | 17 |
| Low erythrocytes; n=326 | 6 |
| High PLT; n=323 | 3 |
| Low leukocytes; n=326 | 3 |
| High leukocytes; n=326 | 18 |
| Low neutrophils + bands; n=324 | 1 |
| High eosinophils; n=324 | 17 |
| High monocytes; n=324 | 2 |
| Low lymphocytes; n=324 | 43 |
Low=lower than LLN, High=greater than ULN. LLN/ULN= Alkaline phosphatase (ALP): \>2 x ULN; aspartate aminotransferase (AST): \>3 x ULN; alanine aminotransferase (ALT): \>3 x ULN; G-Glutamyl transferase (GGT): \>2 x ULN; Bilirubin: \>2 x ULN; blood urea nitrogen (BUN): \>2 x BL; creatinine: \>4 x BL; potassium (K): \<0.9 x LLN/ \>1.1 x ULN; calcium (Ca): \<0.8 x LLN/\>1.2 x ULN; phosphorous (P): \<0.75 x LLN/ \>1.2 5 x ULN
| participants | ABA ~10 mg/kg, OL |
|---|---|
| High ALP, n=331 | 4 |
| High AST, n=331 | 3 |
| High ALT; n=331 | 3 |
| High GGT; n=332 | 17 |
| High bilirubin, n=331 | 1 |
| High BUN; n=310 | 10 |
| High creatinine; n=330 | 5 |
| Low K; n=331 | 7 |
| Low Ca; n=330 | 2 |
| Low P; n=330 | 4 |
| High P, n=330 | 1 |
Low=lower than LLN, High=greater than ULN. LLN/ULN= serum glucose (Glu): \<65 mg/dL/ \>220 mg/dL; fasting serum Glu: \<0.8 x LLN/ \>1.5 x ULN; total protein: \< 0.9 x LLN/ \>1.1 x ULN; albumin:\<0.9 x LLN; uric acid: \>1.5 x ULN. For Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]): Use ≥2 when BL value missing or value ≥4, or when pre-dose=0 or 0.5. Use ≥3 when pre-dose=1. Use ≥4 when pre-dose=2 or 3
| participants | ABA ~10 mg/kg, OL |
|---|---|
| Low Glu; n=245 | 4 |
| High Glu; n=245 | 6 |
| Low protein; n=331 | 3 |
| Low albumin; n=331 | 12 |
| High urine protein; n=312 | 11 |
| High urine Glu; n=312 | 4 |
| High urine blood; n=312 | 27 |
| High leukocyte esterase; n=122 | 10 |
| High urine RBC; n=115 | 22 |
| High urine WBC; n=150 | 45 |
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. Mucosal healing was defined as endoscopic subscore ≤ 1 point
| participants | ABA ~10 mg/kg, MP | Placebo, MP |
|---|---|---|
| OL; Number of Participants With Mayo Endoscopic Subscores Indicating Mucosal Healing (≤1 Point) During OL | 0 | 0 |
The Mayo Scoring system (range 0-12 points, high scores=greater severity of disease) is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Clinical response=reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point. Clinical remission = Mayo score of ≤ 2 points with no individual subscore exceeding 1 point. Change from Baseline= post-Baseline - Baseline value.
No measurements were reported for this outcome.
A electrochemiluminescent immunoassay screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. CTLA4 and Possibly Ig category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.
| participants | ABA ~10 mg/kg, OL |
|---|---|
| Total | 66 |
| CTLA4/Possibly Ig | 59 |
| Ig and/or Ig Junction | 11 |
Participants taking oral corticosteroids (equivalent of ≤ 30 mg prednisone daily) must have met minimum treatment duration at entry into IP and had stable dose for ≥2 weeks prior to entry into the IP.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABA 30/~10 mg/kg,IP1C | — | 22/141 (15.6%) | 49/141 (34.8%) |
| ABA 30/~10mg/kg,IP2C | — | 6/51 (11.8%) | 13/51 (25.5%) |
| ABA 3 mg/kg,IP1C | — | 8/70 (11.4%) | 21/70 (30%) |
| ABA ~10 mg/kg,IP1C | — | 20/139 (14.4%) | 48/139 (34.5%) |
| ABA ~10mg/kg,IP2C | — | 4/50 (8%) | 13/50 (26%) |
| ABA ~10mg/kg, MP | — | 7/65 (10.8%) | 20/65 (30.8%) |
| ABA ~10 mg/kg, OL | — | 66/349 (18.9%) | 137/349 (39.3%) |
| Placebo, IP1C | — | 7/140 (5%) | 45/140 (32.1%) |
| Placebo, MP | — | 4/66 (6.1%) | 24/66 (36.4%) |
| Event | ABA 30/~10 mg/kg,IP1C | ABA 30/~10mg/kg,IP2C | ABA 3 mg/kg,IP1C | ABA ~10 mg/kg,IP1C | ABA ~10mg/kg,IP2C | ABA ~10mg/kg, MP | ABA ~10 mg/kg, OL | Placebo, IP1C | Placebo, MP |
|---|---|---|---|---|---|---|---|---|---|
| COLITIS ULCERATIVEGastrointestinal disorders | 13/141 | 5/51 | 5/70 | 14/139 | 4/50 | 3/65 | 42/349 | 4/140 | 1/66 |
| ABDOMINAL PAINGastrointestinal disorders | 0/141 | 1/51 | 0/70 | 0/139 | 0/50 | 0/65 | 0/349 | 0/140 | 0/66 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 0/141 | 1/51 | 0/70 | 0/139 | 0/50 | 0/65 | 0/349 | 0/140 | 0/66 |
| ANAEMIABlood and lymphatic system disorders | 2/141 | 1/51 | 0/70 | 1/139 | 0/50 | 0/65 | 2/349 | 0/140 | 0/66 |
| SEPSISInfections and infestations | 0/141 | 0/51 | 0/70 | 0/139 | 0/50 | 1/65 | 1/349 | 0/140 | 0/66 |
| PNEUMONIAInfections and infestations | 1/141 | 0/51 | 0/70 | 0/139 | 0/50 | 1/65 | 1/349 | 0/140 | 0/66 |
| VARICELLAInfections and infestations | 0/141 | 0/51 | 0/70 | 0/139 | 0/50 | 1/65 | 0/349 | 0/140 | 0/66 |
| ANAL ABSCESSInfections and infestations | 0/141 | 0/51 | 0/70 | 0/139 | 0/50 | 1/65 | 0/349 | 0/140 | 0/66 |
| APPENDICITISInfections and infestations | 0/141 | 0/51 | 0/70 | 0/139 | 0/50 | 1/65 | 0/349 | 0/140 | 0/66 |
| CLOSTRIDIAL INFECTIONInfections and infestations | 0/141 | 0/51 | 0/70 | 0/139 | 0/50 | 1/65 | 0/349 | 0/140 | 0/66 |
| Event | ABA 30/~10 mg/kg,IP1C | ABA 30/~10mg/kg,IP2C | ABA 3 mg/kg,IP1C | ABA ~10 mg/kg,IP1C | ABA ~10mg/kg,IP2C | ABA ~10mg/kg, MP | ABA ~10 mg/kg, OL | Placebo, IP1C | Placebo, MP |
|---|---|---|---|---|---|---|---|---|---|
| HEADACHENervous system disorders | 17/141 | 3/51 | 7/70 | 12/139 | 6/50 | 3/65 | 24/349 | 12/140 | 5/66 |
| PYREXIAGeneral disorders | 9/141 | 3/51 | 6/70 | 6/139 | 1/50 | 2/65 | 17/349 | 2/140 | 1/66 |
| NASOPHARYNGITISInfections and infestations | 5/141 | 2/51 | 2/70 | 3/139 | 1/50 | 3/65 | 29/349 | 8/140 | 3/66 |
| NAUSEAGastrointestinal disorders | 8/141 | 1/51 | 3/70 | 11/139 | 3/50 | 2/65 | 18/349 | 9/140 | 4/66 |
| BACK PAINMusculoskeletal and connective tissue disorders | 3/141 | 1/51 | 0/70 | 2/139 | 0/50 | 4/65 | 13/349 | 3/140 | 5/66 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 4/141 | 1/51 | 2/70 | 6/139 | 0/50 | 2/65 | 18/349 | 4/140 | 5/66 |
| COUGHRespiratory, thoracic and mediastinal disorders | 6/141 | 1/51 | 2/70 | 4/139 | 1/50 | 4/65 | 13/349 | 3/140 | 5/66 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 3/141 | 1/51 | 1/70 | 2/139 | 0/50 | 2/65 | 22/349 | 5/140 | 2/66 |
| INFLUENZAInfections and infestations | 1/141 | 1/51 | 0/70 | 3/139 | 0/50 | 4/65 | 12/349 | 3/140 | 1/66 |
| ABDOMINAL PAINGastrointestinal disorders | 8/141 | 2/51 | 1/70 | 1/139 | 3/50 | 3/65 | 16/349 | 5/140 | 4/66 |
| Age, Customized(participants) | Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 3 mg/kg | IP1C-Placebo | IP Cohort 2 (IP2C)-ABA 30/~10 mg/kg | IP2C-ABA ~10 mg/kg | Total |
|---|---|---|---|---|---|---|---|
| <30 years | 26 | 23 | 18 | 34 | 12 | 4 | 117 |
| 30-50 years | 70 | 84 | 35 | 73 | 30 | 32 | 324 |
| >50 years | 45 | 32 | 17 | 33 | 9 | 14 | 150 |
| Sex: Female, Male(Participants) | Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 3 mg/kg | IP1C-Placebo | IP Cohort 2 (IP2C)-ABA 30/~10 mg/kg | IP2C-ABA ~10 mg/kg | Total |
|---|---|---|---|---|---|---|---|
| Female | 57 | 52 | 26 | 66 | 21 | 26 | 248 |
| Male | 84 | 87 | 44 | 74 | 30 | 24 | 343 |
| Region of Enrollment(participants) | Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 3 mg/kg | IP1C-Placebo | IP Cohort 2 (IP2C)-ABA 30/~10 mg/kg | IP2C-ABA ~10 mg/kg | Total |
|---|---|---|---|---|---|---|---|
| United States | 43 | 42 | 22 | 55 | 20 | 13 | 195 |
| Ireland | 1 | 0 | 0 | 1 | 0 | 1 | 3 |
| Italy | 7 | 6 | 2 | 3 | 2 | 1 | 21 |
| Switzerland | 1 | 1 | 1 | 2 | 1 | 0 | 6 |
| United Kingdom | 0 | 0 | 0 | 3 | 2 | 4 | 9 |
| India | 12 | 12 | 10 | 10 | 5 | 2 | 51 |
| France | 7 | 12 | 6 | 6 | 1 | 5 | 37 |
| Czech Republic | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Mexico | 20 | 14 | 10 | 8 | 7 | 9 | 68 |
| Puerto Rico | 0 | 1 | 0 | 1 | 0 | 0 | 2 |
| Canada | 9 | 12 | 2 | 13 | 1 | 3 | 40 |
| Brazil | 10 | 5 | 5 | 11 | 4 | 6 | 41 |
| Poland | 2 | 2 | 0 | 1 | 1 | 0 | 6 |
| Belgium | 4 | 6 | 1 | 5 | 0 | 1 | 17 |
| Australia | 8 | 7 | 4 | 13 | 1 | 1 | 34 |
| South Africa | 9 | 8 | 5 | 3 | 2 | 0 | 27 |
| Germany | 2 | 2 | 0 | 1 | 2 | 2 | 9 |
| Netherlands | 2 | 5 | 1 | 2 | 2 | 1 | 13 |
| Korea, Republic of | 4 | 3 | 1 | 2 | 0 | 1 | 11 |
| Participants with Inadequate Response/Intolerance to Prior Anti-Tumor (TNF) Therapy (Infliximab)(participants) | Induction Period Cohort 1 (IP1C)-ABA 30/~10 mg/kg | IP1C-ABA ~10 mg/kg | IP1C-ABA 3 mg/kg | IP1C-Placebo | IP Cohort 2 (IP2C)-ABA 30/~10 mg/kg | IP2C-ABA ~10 mg/kg | Total |
|---|---|---|---|---|---|---|---|
| Inadequate Response/Intolerant to prior Infliximab | 45 | 46 | 24 | 45 | 21 | 21 | 202 |
| No Inadequate Response/Intolerance to Infliximab | 96 | 93 | 46 | 95 | 30 | 29 | 389 |
Showing the first 100 of 144 sites across 19 countries. Choose a country and city above to see the rest.
The record gives a start of Dec 2006, a primary completion of Jun 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2010, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept